International Psoriasis Council

Advancing Knowledge. Improving Care.

Advancing Knowledge. Improving Care.

Dermavant Announces FDA Approval for VTAMA® (Tapinarof) Cream

Dermavant news
Dermavant Sciences announced that VTAMA® (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist, indicated for the topical treatment of plaque psoriasis in adults, has been approved by the U.S. Food and Drug Administration (FDA). VTAMA® cream provides efficacy over 52 weeks and is well-tolerated on the most sensitive skin areas. This approval makes VTAMA® cream the first and only FDA-approved non-steroid topical medication for adults living with plaque psoriasis. The product is expected to be available beginning June 2022.
Dermavant Sciences, a subsidiary of Roivant Sciences

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Categories

Recent Posts

Focus on Psoriasis: A Report from the 2024 American Academy of Dermatology (AAD) Annual Meeting

Psoriasis in Older Patients: Epidemiology, Clinical Features, and Treatment Discussion

SPEVIGO® Receives Approval for Expanded Indications in China and the United States

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.